Clémence Toullec

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer

Clémence Marin, Anthéa Deschamps, Quentin Gerbault, Clémence Toullec et autres

fr (code pays fourni par la source)

Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study

Benoı̂t Rousseau, Marc Hilmi, Antoine Falcoz, Dewi Vernerey et autres

Background: Patients with advanced pancreatic ductal adenocarcinoma (aPDAC) often experience general health decline at diagnosis due to a high-symptom burden. The optimal management of symptoms and/or poor performance status (PS) in these patients remains an unmet medical need. Patients and Methods: In …

us, fr, it, gb (code pays fourni par la source)

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer

Clémence Marin, Anthéa Deschamps, Quentin Gerbault, Clémence Toullec et autres

fr (code pays fourni par la source)

Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)

Jérémie H. Lefèvre, Olivier Dubreuil, Raphaël Colle, David Tougeron et autres

BACKGROUND: Microsatellite instability (MSI) or mismatch‑repair deficiency (dMMR) defines a biologically distinct subgroup of colorectal cancers that are highly responsive to immune checkpoint inhibition. Major and complete pathological responses have been observed with neoadjuvant immunotherapy, raising the possibility of avoiding upfront surgery …

fr (code pays fourni par la source)

Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Francesca Licitra, Kevin Joseph Harrington, Robert I. Haddad et autres

Supplementary material

Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Lisa Francesca Licitra, Kevin Joseph Harrington, Robert I. Haddad, Lillian L. Siu et autres

AbstractPurpose: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that monalizumab plus cetuximab had clinical activity in R/M HNSCC. Patients and Methods: INTERLINK-1 …

ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial.

Filippo Gustavo Dall’Olio, Wael Zrafi, M. Moreau, Rebecca Ibrahim et autres

6047 Background: Anti-PD1 provides clinical benefits in HNSCC, yet biomarkers of response remain poorly defined. In other cancer types, measures of ctDNA shedding, such as TF, have been shown to correlate with treatment outcomes. Little is known about ctDNA shedding in HNSCC …

fr (code pays fourni par la source)

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Francesca Licitra, Kevin Joseph Harrington, Robert I. Haddad et autres

PURPOSE: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that monalizumab plus cetuximab had clinical activity in R/M HNSCC. PATIENTS AND METHODS: INTERLINK-1 …

fr, it, ca, gb, us, tw, jp, be, au, gr, kr, ru, pt, nl, de (code pays fourni par la source)

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study

Jeannie M'Baloula, David Tougeron, Alice Boilève, Elodie Jeanbert et autres

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. The POLO trial showed that olaparib (PARP inhibitor) improved progression-free survival (PFS) but not overall survival (OS), when used as maintenance therapy after ≥ 16 weeks of disease control with first-line platinum-based chemotherapy …

fr (code pays fourni par la source)

869P Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin

Jérôme Fayette, Claire Cropet, Julien Gautier, Clémence Toullec et autres

fr, ch (code pays fourni par la source)

502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial

David Tougeron, JF Émile, Anaïs Bodère, Emilie Barbier et autres

fr (code pays fourni par la source)

Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study

Xavier Adhoute, Alexia Gonzalez, Thomas Lévi‐Strauss, Laurent Mineur et autres

BACKGROUND AND AIMS: The combination of atezolizumab plus bevacizumab (Atz/Bev) has radically changed the treatment strategy for advanced hepatocellular carcinoma (HCC) but raises questions. Our objectives were to determine survival outcomes and safety in a real-life multicenter French cohort, to investigate the …

fr (code pays fourni par la source)